CureVac Share Price: BioNTech Pipeline News – Börse Express

The CureVac takeover by BioNTech is nearing completion – and now, of all times, the buyer is providing positive study data. Time is running out for the remaining CureVac shareholders: the grace period for exchanging their shares ends on December 18th.

Lung cancer study strengthens deal attractiveness

On Saturday, BioNTech presented promising phase 3 data for its cancer drug Gotistobart (BNT316). The study in patients with metastatic non-small cell lung cancer demonstrated a clinically relevant survival benefit – an important milestone for BioNTech’s oncology pipeline.

This development is directly relevant for CureVac shareholders: they receive 0.05363 BioNTech ADSs per CureVac share. If the BioNTech price increases due to positive study results, the value of the exchange offer automatically increases. With a BioNTech price of around $97, the implied value of the CureVac share was around $5.12 to $5.16 on Friday – which is exactly where it was quoted.

After the minimum threshold of 81.74 percent of the shares was significantly exceeded on December 3rd, the takeover is effectively sealed. The remaining grace period until December 18th gives minority shareholders one last opportunity to tender their shares under the same conditions.

Index exit and tax pitfalls

On December 4th, CureVac was removed from the NASDAQ Biotechnology Index – a technical consequence of the successful acquisition. Despite the usually associated selling pressure from index funds, the price remained stable as over 80 percent of the shares had already been tendered.

Anyone who misses the December 18 deadline risks illiquid shares and possible Dutch withholding tax of 15 percent on future dividends. BioNTech is expected to initiate a squeeze-out process in early 2026 to pay out the remaining minority shareholders.

Merging mRNA capacities

With the takeover worth around 1.25 billion US dollars, BioNTech secures the Tübingen research capacities and the intellectual property of CureVac. Although CureVac failed with its first-generation COVID-19 vaccine, its second-generation mRNA technology and patent portfolio remain valuable.

CureVac shares will trade strictly in line with BioNTech until December 18th. If BioNTech continues to rise, the remaining CureVac shareholders will also benefit from the exchange factor. The delisting and full integration into the BioNTech Group are expected to be completed in the first quarter of 2026.